Market Cap 3.80M
Revenue (ttm) 0.00
Net Income (ttm) -7.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -1.60
Volume 45,954
Avg Vol 164,590
Day's Range N/A - N/A
Shares Out 6.03M
Stochastic %K 38%
Beta N/A
Analysts Strong Buy
Price Target $8.50

Company Profile

Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and idiopathic small fiber neuropathy. It also develops CT2000 as a topical agent for the treatment of both...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 265 8266
Address:
4400 Route 9 South, Suite 1000, Freehold, United States
Latest News on CHRO
Chromocell Announces Amendment to Stock Repurchase Plan

Oct 24, 2024, 8:45 AM EDT - 9 months ago

Chromocell Announces Amendment to Stock Repurchase Plan


Chromocell Announces Stock Repurchase Plan

Aug 7, 2024, 8:45 AM EDT - 11 months ago

Chromocell Announces Stock Repurchase Plan